Literature DB >> 8617986

Suppression of antigen-induced arthritis in rabbits by ex vivo gene therapy.

K Otani1, I Nita, W Macaulay, H I Georgescu, P D Robbins, C H Evans.   

Abstract

Gene therapy offers a novel approach to treating human joint diseases such as rheumatoid arthritis. In the present study, we have used the retrovirus, MFG-IRAP, to transfer the human IL-1 receptor antagonist protein (IRAP) gene to rabbits' knees and have assessed its impact on inflammatory and chondrodestructive aspects of the acute phase of antigen-induced arthritis in these joints. Surprisingly, intra-articular expression of IRAP was three- to fivefold higher in arthritic knees than in nonarthritic knees, accumulating to levels of over 20 ng/knee in the highest expressing joints. This level of expression produced a marked chondroprotective effect but a milder anti-inflammatory one. Both the increased cartilage matrix catabolism and the inhibition of matrix synthesis that occur in antigen-induced arthritis were abrogated in the presence of the IRAP gene; the latter effect was particularly strong. Of the indices of inflammation that were examined, only leukocyte influx into the joint space was inhibited, and this effect declined with time. Concentrations of rabbit IL-1 were reduced by the IRAP gene, suggesting inhibition of an autocrine induction loop. These data demonstrate that the course of arthritic disease in the rabbit knee can be altered by genetic manipulation, thus encouraging the further development of gene treatments for human joint diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8617986

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  36 in total

1.  Amelioration of collagen-induced arthritis by CD95 (Apo-1/Fas)-ligand gene transfer.

Authors:  H Zhang; Y Yang; J L Horton; E B Samoilova; T A Judge; L A Turka; J M Wilson; Y Chen
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

Review 2.  IL-1 pathways in inflammation and human diseases.

Authors:  Cem Gabay; Céline Lamacchia; Gaby Palmer
Journal:  Nat Rev Rheumatol       Date:  2010-02-23       Impact factor: 20.543

3.  Safety of extended treatment with anakinra in patients with rheumatoid arthritis.

Authors:  R M Fleischmann; J Tesser; M H Schiff; J Schechtman; G-R Burmester; R Bennett; D Modafferi; L Zhou; D Bell; B Appleton
Journal:  Ann Rheum Dis       Date:  2006-01-05       Impact factor: 19.103

4.  Biomechanical signals suppress proinflammatory responses in cartilage: early events in experimental antigen-induced arthritis.

Authors:  Mario Ferretti; Robert Gassner; Zheng Wang; Priyangi Perera; James Deschner; Gwendolyn Sowa; Robert B Salter; Sudha Agarwal
Journal:  J Immunol       Date:  2006-12-15       Impact factor: 5.422

Review 5.  Gene therapy for rheumatoid arthritis.

Authors:  P D Robbins; C H Evans; Y Chernajovsky
Journal:  Springer Semin Immunopathol       Date:  1998

6.  Gene therapy in autoimmune diseases.

Authors:  C H Evans; J D Whalen; C H Evans; S C Ghivizzani; P D Robbins
Journal:  Ann Rheum Dis       Date:  1998-03       Impact factor: 19.103

Review 7.  Gene therapy for rheumatoid arthritis. Theoretical considerations.

Authors:  Y Chernajovsky; A Annenkov; C Herman; K Triantaphyllopoulos; D Gould; H Dreja; S P Moyes; J L Croxford; R A Mageed; O L Podhajcer; D Baker
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

8.  Clinical responses to gene therapy in joints of two subjects with rheumatoid arthritis.

Authors:  Peter Wehling; Julio Reinecke; Axel W A Baltzer; Markus Granrath; Klaus P Schulitz; Carl Schultz; Rüdiger Krauspe; Theresa W Whiteside; Elaine Elder; Steven C Ghivizzani; Paul D Robbins; Christopher H Evans
Journal:  Hum Gene Ther       Date:  2009-02       Impact factor: 5.695

Review 9.  Perspectives on the use of gene therapy for chronic joint diseases.

Authors:  Steven C Ghivizzani; Elvire Gouze; Jean-Noel Gouze; Jesse D Kay; Marsha L Bush; Rachael S Watson; Padraic P Levings; David M Nickerson; Patrick T Colahan; Paul D Robbins; Christopher H Evans
Journal:  Curr Gene Ther       Date:  2008-08       Impact factor: 4.391

Review 10.  Gene therapy of the rheumatic diseases: 1998 to 2008.

Authors:  Christopher H Evans; Steven C Ghivizzani; Paul D Robbins
Journal:  Arthritis Res Ther       Date:  2009-01-30       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.